Fill Out Your Profile to share more about you. Learn more...

Promising New Treatment for Metastatic Breast Cancer


Promising New Treatment for Metastatic Breast Cancer

Nov 2, 2023

Dr. Aditya Bardia discusses encouraging results from a study on a new medicine for hormone receptor-positive, HER2-negative breast cancer.

At the European Society for Medical Oncology (ESMO) 2023 Congress Aditya Bardia, MD, MPH, presented results from the TROPION-Breast01 trial, which is comparing a new antibody-drug conjugate, datopotamab-deruxtecan (dato-DXd), to doctors’ choice of chemotherapy for inoperable or metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown while being treated with hormonal therapy and also had been treated with chemotherapy.

Listen to the podcast to hear Dr. Bardia explain:

  • what an antibody-drug conjugate is
  • the design of the TROPION-Breast01 study and the first results
  • dato-DXd side effects
  • how dato-DXd might fit into the current treatment landscape for metastatic breast cancer

Listen now or read the transcript.